Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 1999

View Archived Issues

Selected purine analogues tested as angiogenesis inhibitors

Vivus terminates agreement with Bio-Medic Institute

HMR grants Fujisawa option to license malononitrilamide compounds

Major clinical study demonstrates efficacy and safety of Aviron's intranasal flu vaccine

Epimmune receives notice of allowance for patent covering vaccine technology

Zadaxin triple therapy shows promising results in preclinical model of colorectal cancer

Avigen licenses AAV-factor IX technology from the Children's Hospital of Philadelphia

York Medical gives update on development of anti-EGF receptor MAb for cancer Rx/Dx

Oral hepatitis B plant vaccine begins clinical trials in U.S.

ABT-431: the first D1 agonist with demonstrated antiparkinsonian activity in patients

U.S. patent issues for Celgene's ADHD treatment

NeXstar begins enrolling patients in U.S. phase I trial of NX-211

Onconase/interferon combination exerts synergistic antitumor activity in vitro

Broad-spectrum antivirals with heterocyclic structure developed at BioChem Pharma

Agents for AIDS extracted from plant source

Tetrionics will supply 2ME2 for EntreMed's preclinical testing program

Insulin secretion enhancers under study at Lilly for use in conditions of impaired glucose disposal

Bristol-Myers Squibb patents new series of CDK inhibitors

Novel pyridazines from Kowa inhibit cytokine production

Antitumor spectrum of Sch-66336 determined in human tumor cloning assay

New integrin receptor antagonists in the Merck pipeline

KRP-197: new bladder-selective antimuscarinic agent in clinical trials for bladder dysfunction

Xenova sells MetaXen to Exelixis

Licensing opportunity from NIH: method of preventing or reducing ischemic injury of the heart

Planned Rhone-Poulenc/Hoechst merger moves forward on schedule

Potent, orally active AVP receptor antagonist increases urine output in rats

Satellite symposium on antiarrhythmics underlines particular promise of dronedarone

TT-232, a new somatostatin analogue, effective against neurogenic and non-neurogenic inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...